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We reported data concerning the Gas Chromatography–Mass Spec-
trometry (GC–MS) based metabolomic analysis of amniotic ﬂuid (AF)
samples obtained from pregnant women infected with Human Cyto-
megalovirus (HCMV). These data support the publication “Primary
HCMV Infection in Pregnancy from Classic Data towards Metabo-
lomics: an Exploratory analysis” (C. Fattuoni, F. Palmas, A. Noto, L.
Barberini, M. Mussap, et al., 2016) [2]. GC–MS andMultivariate analysis
allow to recognize the molecular phenotype of HCMV infected fetuses
(transmitters) and that of HCMV non-infected fetuses (non-transmit-
ters); moreover, GC–MS and multivariate analysis allow to distinguish
and to compare the molecular phenotype of these two groups with a
control group consisting of AF samples obtained in HCMV non-
infected pregnant women. The obtained data discriminate controls











L. Barberini et al. / Data in Brief 9 (2016) 220–230 221signiﬁcant difference was found between transmitters and non-
transmitters.
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Metabolomics
ore speciﬁc sub-
ject areaClinical Metabolomicsype of data GC–MS data matrix, Figures, Tables
ow data was
acquiredAgilent 5975C mass spectrometer interfaced to the 7820 gas chromatograph.
MetaboAnalyst web-toolata format Processed
xperimental
factorsAfter amniocentesis, AF samples were stored at 4 °C for 1-3 h maximum, ali-
quoted as a whole (without centrifugation) and transferred at 80 °C.xperimental
featuresSamples were derivatized and analyzed by GC–MS. Metabolites were identiﬁed
by AMDIS using GMD and in-house made libraries. Multivariate analysis was
performed by MetaboAnalyst 3.0.ata source
locationPavia, Italyata accessibility Data are within this articleD
Value of the data
 GC–MS analysis enabled to detect 58 metabolites; 50 of them have been accurately identiﬁed. To
our knowledge, our data matrix is the ﬁrst report on AF characterization in maternal HCMV
infection.
 These data open new insights on the clinical utilization of the AF sample as diagnostic bioﬂuid for
metabolomics investigations.
 We applied the Receiving Operating Characteristic (ROC) analysis, based on the cross validation
(CV) strategy. CV provides an unbiased assessment of the model without reducing the training data
set; in other words, CV avoids overﬁtting because the training sample is independent from the
validation sample. Ultimately, CV selects the algorithm with the smallest estimated risk. All these
data can be useful for further design of experiments on this topic.1. Data
The GC–MS data analysis of AF samples originated a matrix spreadsheet (Microsoft Excel
s
,
Microsoft Co, Redmond, WA, USA) containing the detected metabolites and their respective con-
centrations (Supplementary Data). Columns contain: human metabolome database identiﬁcation
(HMDB-ID) [1], metabolites name and, from #1 to #64, sample identiﬁcation. Data in black corre-
spond to healthy controls (n¼23); those in red to transmitters (n¼20); and those in blue to non-
transmitters (n¼21).2. Experimental design, materials and methods
Data originated from the analysis of AF samples obtained from HCMV infected women. The study
population included pregnant women transmitting the infection to the fetus and pregnant women
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asymptomatic, have been examined. All AF samples were obtained after amniocentesis at the
Departments of Obstetrics and Gynecology, Fondazione Istituto di Ricovero e Cura a Carattere Sci-
entiﬁco (IRCCS) Policlinico San Matteo, Pavia, Italy and were analyzed as reported previously [2]. The
multivariate models were built by using the Partial Least Square-Discriminant Analysis (PLS-DA)
(MetaboAnalyst 3.0, http://www.metaboanalyst.ca/) [3–5], as detailed in the research paper [2].
Power Analysis test, notably permutation test and the optimal sample size, was applied to assess the
needful sample size for detecting the effect of interest with a given degree of conﬁdence.
2.1. Data analysis and validation
The overall selected mothers were 63; however, one transmitter mother had a twin pregnancy: the
ﬁrst one baby was HCMV-infected (sample #46) and the second one was not (sample #61). Meta-
bolites termed U483, U1437, U1751 and U1804 are unknown; they were found in most samples.
Metabolites termed A192013, A196015, A203003, and A203005 have been deﬁned by the MPIMP ID in
the Golm Metabolome Database (GMD). By using the “Spectrum Library Search & Prediction of
Functional Groups” web-tool [6], we found that these metabolites matched with unknown metabo-
lites stored in GMD. All the remaining metabolites were identiﬁed by comparing the retention time
and the mass spectrum with those of commercially available reference standards (Sigma-Aldrich s.r.l.,
Milan, Italy) as well as with those homemade (Department of Chemical and Geological Sciences,
University of Cagliari, Italy).
The MetaboAnalyst tool was used for the validation of the following HCMV models: controls vs.
transmitters, controls vs. non-transmitters, transmitters vs. non-transmitters, and ACI (Asymptomatic
Congenital Infection) vs. SCI (Symptomatic Congenital Infection).
2.1.1. Controls vs. transmitters model
Estimation was performed using a pre-processing step consisting in the exclusion of features with
missing data greater than 50%, and the evaluation of missing values lower than 50% as half of the
minimum value measured. In order to identify and remove variables that are unlikely to be of use in
data modeling, a ﬁltering process was applied on data [7]. Relative standard deviation (RSD¼SD/
mean) was applied to identify uninformative variables in dataset. Successively, data were normalized
with a 3 steps procedure: i) samples normalization to the sum of all the acquired values as a general-
purpose adjustment for the differences among samples; ii) data transformation through a generalized
logarithm transformation; iii) scaling procedure by means of auto scaling procedure. A PLS-DA model
was generated; healthy subjects were labeled as class 1, and transmitters as class 2. The maximum
number of components calculated for the classiﬁcation was 5. The corresponding R2, and Q2 values
are reported below for each component (Table 1).
The Cross validation (CV) method employed for this study was the 10-fold CV, with Q2 as mea-
sured performance. Since PLS-DA tends to over ﬁt data, the model needs to be validated in order to
understand whether the separation is statistically signiﬁcant or it is due to random noise. This
hypothesis was tested using the permutation tests: in each permutation, a PLS-DA model is built
between the data (X) and the permuted class labels (Y) using the optimal number of components
determined by previous cross validation calculations and based on the original class assignment. The
ratio of the between sum of the squares and the within sum of squares (B/W-ratio) is calculated for
the class assignment prediction of each model. If the B/W ratio of the original class assignment is aTable 1
R2 and Q2 values for controls vs. transmitters model.
Measure 1 comps 2 comps 3 comps 4 comps 5 comps
Accuracy 0.84 0.88 0.86 0.9 0.88
R2 0.59105 0.75522 0.84065 0.88317 0.9086
Q2 0.43483 0.58123 0.46706 0.37141 0.28953
L. Barberini et al. / Data in Brief 9 (2016) 220–230 223part of the distribution based on the permuted class assignment, the contrast between the two class
assignments cannot be considered signiﬁcant from a statistical point of view. The following graph,
suggested by Bijlsma et al. [8], helps to evaluate whether a class assignment is appropriate or mis-Fig. 1. Permutation test; Select test statistic: Separation distance (B/W), set permutation numbers:100 po0.01.
Fig. 2. ROC curves, based on the cross validation (CV) performance. The ROC curve is the curve for the model with the least
number of features (2), with 95% conﬁdence interval computed for the model.
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highlighted bar represents the original sample. The further to the right of the distribution, the more
signiﬁcant is the separation between the two groups.
By using the Biomarker Analysis tool, it is possible to develop the ROC analysis for the model (Fig. 2).
Multivariate ROC plot based exploratory analysis (Explorer) performs automated important feature iden-
tiﬁcation, and performance evaluation. ROC curve analyses are based on partial least squares discriminant
analysis (PLS-DA). ROC plots are generated by Monte-Carlo cross validation (MCCV) using balanced sub-
sampling. In each MCCV, two thirds (2/3) of the samples are employed to evaluate the feature importance.
The top 2, 3, 5, 10…100 (max) important features are then exploited to build classiﬁcation models, which
are validated on the remaining 1/3 of the samples. The procedure is replicated many and many times in
order to calculate performance, and conﬁdence interval of each model. Several algorithms are available for
classiﬁcation, and feature ranking methods: in our calculations, the feature ranking method, PLS-DA
algorithm with two latent variables (LV) was applied.
2.1.2. Controls vs. non-transmitters model
The methods used in this data set are the same used in the previous model. The 10-fold Cross
validation, with Q2 as measured performance, was again the CV method of choice (Table 2).Table 2
R2 and Q2 values for controls vs. non-transmitters model.
Measure 1 comps 2 comps 3 comps 4 comps 5 comps
Accuracy 0.86 0.88 0.88 0.92 0.88
R2 0.70368 0.78236 0.87182 0.91832 0.94438
Q2 0.49923 0.54274 0.57553 0.62088 0.6229The permutation test is showed in Fig. 3:Fig. 3. Permutation Test. Select test statistic: Separation distance (B/W), set permutation numbers:100 po0.01.The histogram in Fig. 3 shows the distribution of the permuted samples. In this case, the high-
lighted bar is close to the right side of the distribution, meaning a statistically signiﬁcant separation
between the two groups. Also the ROC analysis for the model with 2 features delivers good values,
with an area under the curve (AUC) equal to 0.94 (Fig. 4).
Fig. 4. ROC plot for the PLS-DA model.
Table 3
R2 and Q2 values for transmitters vs. non-transmitters model.
Measure 1 comps 2 comps 3 comps 4 comps 5 comps
Accuracy 0.46 0.44 0.46 0.46 0.44
R2 0.35779 0.46634 0.58919 0.69187 0.79734
Q2 0.10805 0.13862 0.36437 0.63298 1.0741
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The whole set of methods applied for these data is the same of that used for the previous models
(Table 3).
Since this model shows unusual Q2 residuals; such values should be investigated. In the case it is
not possible, the advice is either to use all the latent variables available or to add more samples for a
more reliable model.
The histogram in Fig. 5 shows the distribution of the permuted samples. In this case, the high-
lighted bar is close to the left side of the distribution and this means a statistically non-signiﬁcant
separation between the two groups (p¼0.37). Also the ROC curve analysis for the model with 2 fea-
tures gave an unsatisfactory result.
Fig. 5. Permutation test.
Fig. 6. ROC plot for the model (AUC¼0.663).
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The same statistical methods chosen for the previous models were applied to these data (Fig. 6).
PLS-DA cross validation for the comparison between ACI vs. SCI is reported in Table 4.
Similarly to the previous model, unusual Q2 residuals are observed. Again, investigation on Q2
residuals, and the employment of scores plot on “alien samples”/outliers may help to remove these
“errors”. If this is not possible, the addition of other samples or the inclusion of much more latent
variables (principal components) should be considered for a more reliable model.
The histogram in Fig. 7 shows the distribution of the permuted samples. In this case, the high-
lighted bar is close to the left side of the distribution, representing a statistically non-signiﬁcant
separation between the two groups (p¼0.99). Furthermore, the ROC curve calculations for the model
with 2 features delivered an unsatisfactory value (Fig. 8).
The problems reported in this case are probably related to the low number of classes in com-
parison with the intensity of the perturbation to be measured. Basically, a preliminary pilot study for
revealing the presence of the perturbation of interest is recommended. The calculation of the pilot
study size samples is performed considering the “mean precision-based samples size evaluation” [9].
The increase of the precision for each unit in the sample size per group is described by the algorithm
and the rules in Fig. 9.
According to this approach, the minimum sample size selected in an exploratory trial for the
classes is 12 (no prior information). The rationale is based on the precision requested for the groups
mean. Our calculation suggests that the perturbation of interest may be satisfactorily described by our
sample size in the ﬁrsts two models. However, for the differences between transmitter and non-
transmitters, and ACI vs. SCI the precision is not suitable to reveal the perturbation of interest with
statistical signiﬁcance. For these reasons, Power Analysis were performed for each of the four models,
using the proper tool in MetaboAnalyst. Given that a certain effect is present, the Power may be
deﬁned as the probability of detecting that particular effect. For instance, if a study comparing twoTable 4
R2 and Q2 values for ACI vs. SCI model.
Measure 1 comps 2 comps 3 comps 4 comps 5 comps
Accuracy 0.5 0.45 0.5 0.65 0.6
R2 0.35271 0.75519 0.91092 0.96485 0.98726
Q2 0.15551 0.33554 0.25473 0.098897 0.04234
Fig. 7. Permutation test.
Fig. 8. ROC plot for the model (AUC¼0.495).
Fig. 9. Increase of the precision for each unit in the sample size per group.
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several times, a statistically signiﬁcant difference between the two groups should be detected 80% of
the time. Therefore, despite the presence of that effect, 20% of the experiments should not highlight a
statistically signiﬁcant effect. There are three major factors affecting the Power Analysis:
(a) effect size, which is usually deﬁned as the difference of two group means divided by the pooled
standard deviation. When the other factors are equivalent in the groups under study, a larger
effect size will lead to more power.
Fig. 10. Estimation of the effect size in the models. A¼ transmitters vs. non-transmitters. B¼ ACI vs. SCI.
L. Barberini et al. / Data in Brief 9 (2016) 220–230 229(b) degree of conﬁdence, which is usually the p-value cut-off (alpha) for statistical signiﬁcance. When
the other factors are equivalent in the groups under study, reduced power will be observed when
a very high degree of conﬁdence is required.
(c) sample size. Typically, a larger number of samples increases the power. In several cases, the
sample size is of interest for a given power (i.e. 0.8).
Taking into account the comparison between transmitters vs. non-transmitters, and ACI vs. SCI,
with a sample size of 200 subjects, we computed a predicted power of 0.84 for the former model and
0.67 for the latter. Therefore the number of samples should be further increased (Figs. 10a, b).
The effect size is estimated for the “pilot” study [1]. The graph allows for the investigation of the
sample size vs. the statistic power, guiding the study design. The algorithm allows for the exploration
of a range of sample sizes and, following speciﬁcation of FDR, a graph is produced in order to show
the power of analysis in relation to the sample size applied.
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